Scarica l'app Stockscreener
7.89
1.15%
0.09
Dopo l'orario di chiusura:
7.95
0.06
+0.76%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARDX Giù?
Forum
Previsione
Precedente Chiudi:
$7.80
Aprire:
$8
Volume 24 ore:
2.85M
Relative Volume:
0.66
Capitalizzazione di mercato:
$1.92B
Reddito:
$386.15M
Utile/perdita netta:
$-56.39M
Rapporto P/E:
-34.30
EPS:
-0.23
Flusso di cassa netto:
$-55.19M
1 W Prestazione:
+1.68%
1M Prestazione:
+37.46%
6M Prestazione:
+83.92%
1 anno Prestazione:
+44.24%
Intervallo 1D:
$7.79
$8.1144
Intervallo di 1 settimana:
$7.55
$8.40
Portata 52W:
$3.21
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Nome
Ardelyx Inc
Settore
Industria
Telefono
510-745-7047
Indirizzo
34175 ARDENWOOD BLVD., FREMONT, CA
Confronta ARDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
7.89 | 1.90B | 386.15M | -56.39M | -55.19M | -0.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-09 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-09-03 | Ripresa | Raymond James | Strong Buy |
| 2025-06-18 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-02 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-03-07 | Ripresa | Ladenburg Thalmann | Buy |
| 2025-03-04 | Iniziato | BTIG Research | Buy |
| 2024-11-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-07-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | Iniziato | Leerink Partners | Outperform |
| 2023-12-18 | Iniziato | Raymond James | Strong Buy |
| 2023-09-07 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-25 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-11-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | Downgrade | Jefferies | Buy → Hold |
| 2021-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-23 | Iniziato | Wedbush | Outperform |
| 2021-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-20 | Ripresa | Citigroup | Buy |
| 2020-02-18 | Ripresa | Jefferies | Buy |
| 2020-02-12 | Iniziato | Citigroup | Buy |
| 2020-02-10 | Iniziato | Cowen | Outperform |
| 2019-04-08 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-24 | Iniziato | Jefferies | Buy |
| 2018-03-19 | Ripresa | Leerink Partners | Outperform |
| 2017-11-29 | Reiterato | Citigroup | Buy |
| 2017-11-22 | Reiterato | Ladenburg Thalmann | Buy |
| 2017-10-17 | Ripresa | Leerink Partners | Outperform |
| 2016-03-31 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-03-09 | Iniziato | Cantor Fitzgerald | Buy |
| 2016-03-03 | Iniziato | Citigroup | Buy |
Mostra tutto
Ardelyx Inc Borsa (ARDX) Ultime notizie
Is It Too Late To Consider Ardelyx (ARDX) After The Recent Share Price Surge? - simplywall.st
All You Need to Know About Ardelyx (ARDX) Rating Upgrade to Buy - Yahoo Finance Singapore
Palisades Investment Partners LLC Cuts Position in Ardelyx, Inc. $ARDX - MarketBeat
AIGH Capital Management LLC Makes New Investment in Ardelyx, Inc. $ARDX - MarketBeat
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Ardelyx (ARDX) and AxoGen (AXGN) - The Globe and Mail
Ardelyx Investors Appeal Dismissal of Medicare Program Lawsuit - Bloomberg Law News
Ardelyx responds to Zydus Lifesciences acquisition reports - CNBC TV18
Ardelyx stock hits 52-week high at 8.06 USD By Investing.com - Investing.com India
ZYDUS EYES ARDELYX ACQUISITION DEAL - ICICI Direct
Ardelyx: Assessment Of Acquisition Rumors (NASDAQ:ARDX) - Seeking Alpha
ARDX: Wedbush Raises Price Target to $19, Maintains Outperform R - GuruFocus
Ardelyx (NASDAQ:ARDX) Sets New 52-Week High on Analyst Upgrade - MarketBeat
Ardelyx stock hits 52-week high at 8.06 USD - Investing.com
Wedbush Increases Ardelyx (NASDAQ:ARDX) Price Target to $19.00 - MarketBeat
ARDX: Wedbush Raises Price Target to $19, Maintains Outperform Rating | ARDX Stock News - GuruFocus
Lam Research To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Demystifying Ardelyx: Insights From 7 Analyst Reviews - Benzinga
Ardelyx (ARDX) price target increased by 12.82% to 13.46 - MSN
Strength Seen in Ardelyx (ARDX): Can Its 15.0% Jump Turn into More Strength? - Nasdaq
Ardelyx, Inc. (NASDAQ:ARDX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry - simplywall.st
Zydus Gets World’s First Menkes Disease Drug Approval Amid Ardelyx Acquisition Speculation - Citeline News & Insights
Grapevine: Zydus in talks to acquire US biopharma firm; K Raheja mulls IPO - VCCircle
Wedbush Raises Ardelyx Price Target to $19 Amid Outperform Rating - Intellectia AI
Health Care Stocks Split As Deal Talk Lifts Select Names - Finimize
Zydus Lifesciences eyes $2.5 billion US biopharma buyout of Ardelyx: Report - Moneycontrol
Zydus Lifesciences plans to acquire Ardelyx for USD 2.5B - Medical Buyer
Ardelyx stock soars on report of potential Zydus Life acquisition By Investing.com - Investing.com South Africa
Ardelyx stock soars on report of potential Zydus Life acquisition - Investing.com
Ardelyx (NASDAQ:ARDX) Trading Up 10.2%Here's What Happened - MarketBeat
Ardelyx Shares Soar as Analysts Raise Price Targets - StocksToTrade
Ardelyx Stock Surges Amid Upgraded Ratings and Revenue Projections - timothysykes.com
Zydus Lifesciences eyes acquisition of US firm Ardelyx for $2.5 billion | Company Business News - Mint
Ardelyx (ARDX) Surges on Potential Acquisition by Zydus Lifesciences - GuruFocus
Ardelyx: IBSRELA Momentum Drives Opportunity (NASDAQ:ARDX) - Seeking Alpha
Zydus Life may acquire US-firm Ardelyx; may fund deal via QIP - India Infoline
Zydus Life to Acquire Ardelyx, Raise Funds via QIP; Shares Flat - Equitypandit
Zydus Lifesciences in talks to acquire US biopharma firm Ardelyx, may raise ₹5,000 crore via QIP - scanx.trade
Zydus Life may acquire US-firm Ardelyx, may raise funds via QIP to part-fund deal: Exclusive - CNBC TV18
Ardelyx stock rises premarket as Piper sees over 100% upside — says constipation drug 'stole the show' with 2026 guidance - MSN
Lobbying Update: $580,000 of ARDELYX INC. lobbying was just disclosed - Quiver Quantitative
Ardelyx says 2025 total product revenue was about $378M - MSN
Ardelyx, Inc. (NASDAQ:ARDX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Exit Recap: Can Ardelyx Inc continue delivering strong returns2025 Market Sentiment & Real-Time Volume Surge Alerts - baoquankhu1.vn
Insider Buy: Can Ardelyx Inc stock outperform in 2025 bull market2025 Biggest Moves & Consistent Income Trade Ideas - Bộ Nội Vụ
Ardelyx (ARDX) Price Target Increased by 12.82% to 13.46 - Nasdaq
Lobbying Update: $30,000 of ARDELYX INC. lobbying was just disclosed | ARDX Stock News - Quiver Quantitative
Ardelyx Stock Is Rallying – What Is Making Retail So Bullish? - Asianet Newsable
Ardelyx (NASDAQ:ARDX) Stock Price Down 6.8% on Insider Selling - MarketBeat
Are Medical Stocks Lagging Ardelyx (ARDX) This Year? - Yahoo Finance
Ardelyx Inc: Citigroup raises target price to $14 from $11 - marketscreener.com
Ardelyx Inc Azioni (ARDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):